| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 8.80 | 3.6% | 18.8% |
| Total Income | 8.80 | 3.6% | 18.8% |
| Expenditure | 3.33 | 72.8% | 71.2% |
| PBT | -3.10 | 1.3% | 324.7% |
| Net Profit | -4.28 | 30.1% | 478.4% |
| OPM | -35.91% | 1.64pp | 29.01pp |
| NPM | -48.59% | 12.56pp | 41.75pp |
| EPS | -0.29 | 31.8% | 480.0% |
Cumberland Pharmaceuticals Reports Q2 2026 Financial Results and Company Update
05 Aug 2026 · 5 Aug, 2:57 am
Summary
Cumberland Pharmaceuticals reported its second quarter 2026 financial results, highlighted by the successful closing of a $100 million strategic transaction with Apotex Health. This transaction repositions the company as a development-stage biopharmaceutical organization focused on rare diseases. Despite a net loss of $4.1 million for the quarter, which includes discontinued operations, the company returned capital to shareholders via a $1.50 per share special dividend. Cumberland also advanced its clinical pipeline, presenting updated results from its Phase 2 FIGHT DMD trial.
Key Highlights
- 1
Cumberland Pharmaceuticals announced its second quarter 2026 financial results and provided a company update following the successful closing of its Strategic Transaction with Apotex Health.
- 2
The company completed a transaction with Apotex Health, acquiring Cumberland’s portfolio of FDA-approved brands and related commercial organization for $100 million in cash at closing, plus an additional $11 million for inventory and transition services.
- 3
Following the transaction, Cumberland will transition into a development-stage biopharmaceutical organization focused on advancing differentiated medicines for rare diseases.
- 4
Cumberland's Board of Directors declared a special cash dividend of $1.50 per share, paid on July 31, 2026, to shareholders of record as of July 23, 2026.
- 5
The company presented updated results from its Phase 2 FIGHT DMD clinical trial evaluating ifetroban in patients with Duchenne muscular dystrophy-associated cardiomyopathy.
- 6
The net loss for the second quarter of 2026 was $4.1 million, including $1.0 million from discontinued operations.
- 7
At June 30, 2026, Cumberland had approximately $63 million in total assets, including $4 million in cash and cash equivalents, and retired its bank line of credit through a payment of $5.2 million.
Management Comments
A.J. Kazimi
The second quarter marked a defining milestone for Cumberland. With the successful completion of our Strategic Transaction, we have unlocked substantial value for our shareholders, while positioning Cumberland for its next phase as an innovation-focused biopharmaceutical company. We have strengthened our balance sheet, returned capital to shareholders through a special dividend and remain well-capitalized to advance our pipeline of differentiated product candidates designed to address significant unmet medical needs.
Informational and educational content only. Not investment advice.